NCT05713006 2026-04-08
Alectinib Pharmacokinetic in Patients With NSCLC
Instituto Nacional de Cancerologia de Mexico
Phase 1/2 Recruiting
Clinical Trials
5 trialsNCT06624059 2026-04-08
HORIZON 2
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT06862869 2026-04-06
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
Hoffmann-La Roche
Recruiting
NCT04302025 2026-04-03
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Genentech, Inc.
Phase 2 Recruiting
NCT06765109 2026-03-24
ALKAZAR
Nuvalent Inc.
Phase 3 Recruiting